Abstract: A mobile selective catalytic reduction (SCR) system for a gas turbine includes a base trailer and a selective catalytic reduction duct assembly disposed on the base trailer. The selective catalytic reduction duct assembly is configured to be operably coupled with the gas turbine and receive exhaust from the gas turbine. The SCR system also includes a selective catalytic reduction stack configured to be disposed on the base trailer and operably coupled with the selective catalytic reduction duct assembly. The SCR system further includes a self-erecting trailer detachably coupled with the selective catalytic reduction stack and configured to position the selective catalytic reduction stack on the base trailer.

Abstract: A mobile selective catalytic reduction (SCR) system for a gas turbine includes a base trailer and a selective catalytic reduction duct assembly disposed on the base trailer. The selective catalytic reduction duct assembly is configured to be operably coupled with the gas turbine and receive exhaust from the gas turbine. The SCR system also includes a selective catalytic reduction stack configured to be disposed on the base trailer and operably coupled with the selective catalytic reduction duct assembly. The SCR system further includes a self-erecting trailer detachably coupled with the selective catalytic reduction stack and configured to position the selective catalytic reduction stack on the base trailer.

Abstract: Described herein are compositions, kits, and methods for potent delivery to a cell of a subject. The cell can be of a particular cell type, such as a basal cell, a ciliated cell, or a secretory cell. In some cases, the cell can be a lung cell of a particular cell type. Also described herein are pharmaceutical compositions comprising a therapeutic or prophylactic agent assembled with a lipid composition. The lipid composition can comprise an ionizable cationic lipid, a phospholipid, and a selective organ targeting lipid. Further described herein are high-potency dosage forms of a therapeutic or prophylactic agent formulated with a lipid composition.

Abstract: Compositions of polynucleotide(s), pharmaceutical compositions thereof, and methods of use thereof are disclosed. A polynucleotide may encode for a cystic fibrosis transmembrane conductance regulator (CFTR) protein or a functional fragment thereof. The polynucleotide may be assembled with a lipid composition for targeted delivery to a cell or an organ, such as a lung cell or a lung of a subject. Methods for enhancing an expression or activity of CFTR protein in a cell are provided. Methods for treating a subject having or suspected of having a CFTR-associated condition are also provided.

Abstract: Compositions of polynucleotide(s), pharmaceutical compositions thereof, and methods of use thereof are disclosed. A polynucleotide may encode for a cystic fibrosis transmembrane conductance regulator (CFTR) protein or a functional fragment thereof. The polynucleotide may be assembled with a lipid composition for targeted delivery to a cell or an organ, such as a lung cell or a lung of a subject. Methods for enhancing an expression or activity of CFTR protein in a cell are provided. Methods for treating a subject having or suspected of having a CFTR-associated condition are also provided.

Abstract: Compositions of polynucleotide(s), pharmaceutical compositions thereof, and methods of use thereof are disclosed. A polynucleotide may encode for a cystic fibrosis transmembrane conductance regulator (CFTR) protein or a functional fragment thereof. The polynucleotide may be assembled with a lipid composition for targeted delivery to a cell or an organ, such as a lung cell or a lung of a subject. Methods for enhancing an expression or activity of CFTR protein in a cell are provided. Methods for treating a subject having or suspected of having a CFTR-associated condition are also provided.

Abstract: Compositions of polynucleotide(s), pharmaceutical compositions thereof, and methods of use thereof are disclosed. A polynucleotide may be or encode a synthetic transfer ribonucleic acid (tRNA). The polynucleotide may be assembled with a lipid composition for delivery to a cell or an organ, such as a lung cell or a lung of a subject. Methods for enhancing an expression or activity of cystic fibrosis transmembrane conductance regulator (CFTR) protein in a cell are provided. Methods for treating a subject having or suspected of having a CFTR-associated condition are also provided.

Abstract: Compositions of polynucleotide(s), pharmaceutical compositions thereof, and methods of use thereof are disclosed. A polynucleotide may encode for a cystic fibrosis transmembrane conductance regulator (CFTR) protein or a functional fragment thereof. The polynucleotide may be assembled with a lipid composition for targeted delivery to a cell or an organ, such as a lung cell or a lung of a subject. Methods for enhancing an expression or activity of CFTR protein in a cell are provided. Methods for treating a subject having or suspected of having a CFTR-associated condition are also provided.

Abstract: Described herein are compositions, kits, and methods for potent delivery to a ceil of a subject. The cell can be of a particular cell type, such as a basal cell. In some cases, the cell can be a lung cell of a particular cell type. Also described herein are pharmaceutical compositions comprising a therapeutic or prophylactic agent assembled with a lipid composition. Tire lipid composition can comprise an ionizable cationic lipid, and a selective organ targeting lipid. The lipid composition can further comprise a phospholipid. Further described herein are high-potency intravenous dosage forms of a therapeutic or prophylactic agent formulated with a lipid composition.

Abstract: A delivery system for an implantable vaso-occluding device. A non-planar heating chamber is disposed proximate to a distal end of an advancing member. Protruding from an interior surface of the non-planar heating chamber is a detachment fiber made from a polymeric material and having a closed distal end. At least one heating element is disposed on the interior surface of the non-planar heating chamber to produce sufficient heat to sever the detachment fiber. An articulation point is established between the vaso-occluding device and the delivery system. The vaso-occluding device remains at all times substantially self-centered while being advanced.

Abstract: A massage device for reducing arm pump is disclosed. The massage device includes a massage member disposed on a pair of handlebars used to steer a vehicle. The massage member can have various mounting methods to the handlebars. The massage member can include a variety of members having different dimensions and contours, and relieves the effects of arm pump when a rider presses his or her forearm against the massage device and moves it, either back and forth, or from side to side, thereby massaging the forearm muscle and relieving the effect of arm pump.

Abstract: A concrete panel system includes first, second, and third rectangular precast concrete panels, each defining a respective top edge, bottom edge, and first and second lateral edges. A first type connector is formed in the concrete material at least along the top edge of the first panel and along the first lateral edge of the first panel. A second type connector is formed in the concrete material at least along the second lateral edge of the second panel, and along the bottom edge of the third panel. The first type connector and the second type connector are configured to connect together so as to form a cavity between the respective panel edges. This cavity extends along the first lateral edge of the first panel to facilitate positioning rebar between adjacent panels.

Abstract: A delivery system for an implantable vaso-occluding device. A non-planar heating chamber is disposed proximate to a distal end of an advancing member. Protruding from an interior surface of the non-planar heating chamber is a detachment fiber made from a polymeric material and having a closed distal end. At least one heating element is disposed on the interior surface of the non-planar heating chamber to produce sufficient heat to sever the detachment fiber. An articulation point is established between the vaso-occluding device and the delivery system. The vaso-occluding device remains at all times substantially self-centered while being advanced.

Abstract: A concrete panel system includes first, second, and third rectangular precast concrete panels, each defining a respective top edge, bottom edge, and first and second lateral edges. A first type connector is formed in the concrete material at least along the top edge of the first panel and along the first lateral edge of the first panel. A second type connector is formed in the concrete material at least along the second lateral edge of the second panel, and along the bottom edge of the third panel. The first type connector and the second type connector are configured to connect together so as to form a cavity between the respective panel edges. This cavity extends along the first lateral edge of the first panel to facilitate positioning rebar between adjacent panels.

Abstract: A concrete panel system includes first, second, and third rectangular precast concrete panels, each defining a respective top edge, bottom edge, and first and second lateral edges. A first type connector is formed in the concrete material at least along the top edge of the first panel and along the first lateral edge of the first panel. A second type connector is formed in the concrete material at least along the second lateral edge of the second panel, and along the bottom edge of the third panel. The first type connector and the second type connector are configured to connect together, and a cavity is formed between the respective panel edges. This cavity extends along both the top edge of the first panel and the first lateral edge of the first panel to facilitate positioning reinforcing bar traversing a corner of the first or second panel.

Abstract: A concrete panel system includes first, second, and third rectangular precast concrete panels, each defining a respective top edge, bottom edge, and first and second lateral edges. A first type connector is formed in the concrete material at least along the top edge of the first panel and along the first lateral edge of the first panel. A second type connector is formed in the concrete material at least along the second lateral edge of the second panel, and along the bottom edge of the third panel. The first type connector and the second type connector are configured to connect together, and a cavity is formed between the respective panel edges. This cavity extends along both the top edge of the first panel and the first lateral edge of the first panel to facilitate positioning reinforcing bar traversing a corner of the first or second panel.

Abstract: A concrete panel system includes first, second, and third rectangular precast concrete panels, each defining a respective top edge, bottom edge, and first and second lateral edges. A first type connector is formed in the concrete material at least along the top edge of the first panel and along the first lateral edge of the first panel. A second type connector is formed in the concrete material at least along the second lateral edge of the second panel, and along the bottom edge of the third panel. The first type connector and the second type connector are configured to connect together, and a cavity is formed between the respective panel edges. This cavity extends along both the top edge of the first panel and the first lateral edge of the first panel to facilitate positioning reinforcing bar traversing a corner of the first or second panel.

Abstract: A stud spacer for a metal wall having a series of spaced apart studs with each stud having a pair of flanges and an interconnected web with the web having an opening therein. Connected between each pair of consecutive studs is a stud spacer. Each stud spacer includes a pair of end flanges that are secured to the web of an adjacent stud. In addition, each stud spacer includes a projection that projects through an opening in the adjacent stud and extends into an opening or slot in an adjacent stud spacer such that the respective stud spacers are effectively linked or connected by the projections of the various stud spacers found in the metal wall.

Abstract: The present invention relates to growing anaerobic bacteria by measuring the reduction potential of a growth media at a start time and determining a grow time by correlating the start time reduction potential with said reduction coefficient to calculate when said second anaerobic fermentation system will reach a sufficiently low oxygen concentration to enable growth for an anaerobic bacteria, then adding the anaerobic bacteria to the growth media at a time no sooner than the grow time.

Abstract: A combination stud and bridging member for use in a metal wall. The stud includes a web and a pair of flanges with the web including first and second sides and having a depression formed therein. Adapted to engage or extend through the web, the bridging member includes first and second end portions. One end portion includes a concave shaped recess that when disposed adjacent the stud accommodates the depression formed in the web. Disposed on the end portion of the bridging member having the concave recess is a projection receiver. Disposed on the opposite end of the bridging member is a projection. In a wall structure, the bridging members are adapted to extend between the studs. More particularly, the projections of the bridging members extend through openings formed in the web of the studs and into the projection receivers of adjacent bridging members to form an interlocked relationship.